Edition:
United Kingdom

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

136.29USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$136.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
196,815
52-wk High
$169.58
52-wk Low
$112.15

Latest Key Developments (Source: Significant Developments)

STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Steadymed Ltd ::‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​.‍INVALIDITY DECISION WILL PRECLUDE UNITED THERAPEUTICS FROM ASSERTING '393 PATENT PRIOR TO STEADYMED'S LAUNCH OF ITS TREVYENT PRODUCT​.‍FDA REGULATIONS REQUIRE THAT UNITED THERAPEUTICS "PROMPTLY NOTIFY FDA TO…WITHDRAW PATENT" FROM FDA'S "ORANGE BOOK."​.  Full Article

United Therapeutics Corp reports third quarter 2017 financial results
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - United Therapeutics Corp :United Therapeutics Corporation reports third quarter 2017 financial results.Q3 revenue $446 million versus I/B/E/S view $426.4 million.United Therapeutics Corp - qtrly ‍SHR $6.27​.United Therapeutics Corp - qtrly ‍non-GAAP earnings per diluted share $4.69​.Qtrly ‍non-GAAP earnings, per diluted share $4.69​.Q3 earnings per share view $3.87 -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system
Monday, 23 Oct 2017 

Oct 23 (Reuters) - United Therapeutics Corp :United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system.United Therapeutics Corp - ‍launch of TD-300/A planned for mid-2018​.  Full Article

United Therapeutics Corp Q2 income per diluted share $4.39
Thursday, 28 Jul 2016 

United Therapeutics Corp Qtrly Non : United Therapeutics Corp qtrly net income, per diluted share $4.39 . Q2 earnings per share view $3.22, revenue view $395.0 million -- Thomson Reuters I/B/E/S . United Therapeutics Corporation reports second quarter 2016 financial results . Q2 revenue $400 million versus I/B/E/S view $395 million .Gaap earnings, per diluted share $4.55.  Full Article

United Therapeutics Corp says Roger Jeffs steps down as president and co-CEO
Thursday, 28 Apr 2016 

United Therapeutics Corp:Says Roger Jeffs steps down as president and co-chief executive officer.Says David Zaccardelli steps down as executive vice president and chief operating officer.United Therapeutics Corp says David Zaccardelli, steps down as executive vice president and chief operating officer.United Therapeutics Corp says Michael Benkowitz promoted to president and chief operating officer.United Therapeutics Corp says Martine Rothblatt, remains chairman of board and becomes sole chief executive officer.Says Michael Benkowitz promoted to president and chief operating officer.United therapeutics corp says Jeffs will become a senior advisor to company.  Full Article

Astellas faces U.S. probe over patient assistance charity support

BOSTON, Nov 15 Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs.